Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma
1 Jun 2013
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma
Maintenance therapy with multi-targeted drug pazopanib delays relapse of advanced ovarian cancer
Adding GM-CSF to ipilimumab improves survival compared to ipilimumab alone
Overview of the EurocanPlatform
Landmark cooperative projects in Portugal
Excellence in comprehensive cancer care
Manchester Cancer Services
Establishment of the EurocanPlatform
Evolution of the EurocanPlatform
Institute Jules Bordet and the OECI
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours
Epidemiology of central nervous system germ cell tumours